SEGMENT 01
Engagement-optimised, clinically shallow. Hundreds of apps compete for attention while failing to deliver measurable psychological outcomes. High churn, low clinical credibility.
SEGMENT 02
Operating in a largely analogue environment. No digital infrastructure to scale delivery, manage patient outcomes, or receive qualified referrals. Underserved and underdigitised.
SEGMENT 03
Generic EAP offerings with no measurable outcomes. Employers face growing regulatory pressure on ESG and employee wellbeing, but the market has not delivered credible tools to satisfy it.
THE OPPORTUNITY
No platform currently connects all three. Aureum is building the infrastructure that sits between individuals, clinicians, and organisations, capturing value at every connection point in the network.
B2C · Tier 01
Freemium to subscription. Premium unlocks advanced programmes, personalised clinical pathways, and direct practitioner access.
TARGET ARPU
£8–18 / mo
B2B · Tier 02
SaaS licensing for clinics and independent practitioners. Seat-based pricing with platform infrastructure and referral network access.
TARGET ACV
£3–12K / clinic
B2B · Tier 03
Per-employee-per-month pricing with annual contracts. Executive tier priced separately. Highest ARPU segment with enterprise contract potential.
TARGET ACV
£15–80K / org
Mental health service demand has structurally increased since 2020. NHS capacity has not kept pace. The private digital market is absorbing that overflow, and Aureum is built for it.
UK employers now face regulatory and ESG pressure to demonstrate employee mental health investment. Generic programmes don't satisfy this requirement. Aureum does.
Private psychology practices are actively seeking digital infrastructure. No credible platform serves them. Aureum's clinical tier enters an underserved, high-value segment.
As the clinical network grows, it makes the consumer tier more valuable. As the user base expands, it creates sustainable patient flow for clinics. The three tiers reinforce each other.
Aureum is founder-led, founder-funded at inception, and 100% IP-owned by the founder. Ahd Mahmoud holds Aureum Global Ltd as founder, director, and majority shareholder.
Her background combines lived experience navigating psychological adversity, academic training in psychology, and a systems-level understanding of what clinical infrastructure, and its absence, actually produces. This is not a market opportunity she identified from the outside. It is a problem she lived.
// Founder Profile
Request our full investor documentation, financial model, and founder presentation. We respond to all serious enquiries within 48 hours.